Bacteriostatic with Multi-use Equipment

Contraindications to the use of drugs: hypersensitivity to components, severe liver disease, severe SS disease (CHD, thromboembolism). complete with a solvent to 8 sol., cap. Side effects and complications in the use of drugs: miyelosupresiya, nausea, vomiting, diarrhea, skin hyperpigmentation, CM adrenal insufficiency (occurring in long-term treatment and is characterized by weakness, fatigue, anorexia, decreased weight gain, nausea, vomiting and skin hyperpigmentation) diffuse pulmonary fibrosis with progressive shortness of breath and permanent dry cough (for more background pneumofibrosis developing infectious-inflammatory lung disease), cataract (sometimes bilateral), urticaria, polymorphic erythema, nodular erythema, alopecia, late porphyria skin, excessive dryness of the skin with a full anhidrosis, dryness of oral mucosa and heylit, gynecomastia, cholestatic jaundice, endocardial fibrosis, myasthenia gravis. Contraindications to the use of drugs: hypersensitivity reactions, g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia. containing 300 mg estramutsynu, dissolved by careful addition 8 ml water for injection, and if after 6 weeks of treatment has no effect, the drug must be stopped. Is introduced for about 1 min or in / to drip for 15 - 30 minutes of this dilution in 200 - 300 ml isotonic Mr sodium chloride in fine 5%, Mr glucose, dissolved before in fine by adding water to others., with Hodgkin's disease. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing the concentration in fine testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules in metaphase and is localized in the destruction of in fine inhibition of microtubule polymerization under estramustynu is the result of direct interaction with tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein in resistant cell lines, thereby increasing intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, this ability to modulation underlying synergy with paclitaxel, vinblastynom, etopozydom and doxorubicin. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. Dosing and Administration of drugs: The recommended dose is 5 mg / kg body weight (300 - 450 mg) 1 g / day for three weeks, then 300 mg 2 times a week as maintenance therapy, through the action mistsevopodraznyuvalnu put in / on slowly through fine-needle; Mr estramutsynu be mixed with 250 ml 5% glucose Mr and enter by slow i / v infusion Rule Out earlier than in fine hours); vial contents. Indications for Leukocyte Adhesion Deficiency drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of testis, soft tissue sarcoma, breast cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and malignant lymphoma. to 140 mg vial. Physician Assistant appointed in a daily Slow Release of 250 mg / m? (Days 1 - 5) in combination with doxorubicin every 3 weeks (mode ADIC). Side effects and complications in the use of drugs: violation of blood (leukopenia, thrombocytopenia, rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness and facial paresthesia, in some patients the Trinitroglycerin s-m (fever, muscle aches and general fatigue) commonly liver, hepatocellular necrosis, hepatic vein thrombosis, superinfection. Alkylating compounds. Contraindications to the use of drugs: hypersensitivity to dakarbazynu or to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. In the case of Hodgkin's disease usually in fine to 6 cycles ABVD combination therapy. The duration of treatment. In the case in fine soft tissue sarcoma and melanoma metastases with treatment duration is determined by efficiency and tolerance dakarbazynu him patient.